The Montana Legislature has introduced Senate Bill 535, a significant piece of legislation aimed at expanding access to experimental treatments for patients with serious medical conditions. Introduced on April 29, 2025, the bill seeks to address the growing demand for investigational drugs, biological products, and devices that are not yet fully approved by regulatory agencies.

The main provisions of SB 535 allow health care facilities to approve the use of experimental treatments and enable health plans, third-party administrators, and governmental agencies to cover the costs associated with these treatments. Notably, the bill also stipulates that patients' heirs will not be held liable for any outstanding debts related to experimental treatments if the patient dies during the course of such treatment. This provision aims to alleviate financial burdens on families during difficult times.

Another critical aspect of the bill is the protection it offers to health care providers. Under SB 535, licensing boards are prohibited from taking disciplinary action against providers solely based on their recommendations for experimental treatments. This measure is designed to encourage medical professionals to explore innovative treatment options without fear of repercussions.

The bill has sparked notable discussions among lawmakers and stakeholders. Supporters argue that it represents a crucial step toward patient autonomy and access to potentially life-saving treatments. However, some opponents express concerns about the safety and efficacy of unapproved treatments, fearing that the bill may lead to exploitation of vulnerable patients.

Economically, SB 535 could have significant implications for the health care industry in Montana. By facilitating access to experimental treatments, the bill may encourage investment in local health care facilities and attract patients seeking cutting-edge therapies. However, the financial impact on insurance providers and the potential for increased health care costs remain points of contention.

As the legislative process continues, experts suggest that the outcome of SB 535 could set a precedent for how states approach the regulation of experimental treatments in the future. The bill's progress will be closely monitored by both advocates and critics as it moves through the legislative process, with potential implications for patient care and health policy in Montana and beyond.